PP
MLYS icon

PDT Partners’s Mineralys Therapeutics MLYS Stock Holding History

PDT Partners’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,238
Closed -$148K – 785
2024
Q3 		$148K Buy
+12,238
New +$148K 0.01% 675
2024
Q1 		– Sell
-13,912
Closed -$120K – 665
2023
Q4 		$120K Hold
13,912
– – 0.01% 515
2023
Q3 		$132K Buy
+13,912
New +$181K 0.02% 545

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

PDT Partners's MLYS Position: Q4 2024 in Review

PDT Partners sold out of Mineralys Therapeutics (MLYS) in Q4 2024, closing a stake of 12,238 shares — an estimated $148K sold.

PDT Partners first reported a position in MLYS in Q3 2023 and held it in 3 quarters. The position peaked at $148K in Q3 2024. 108 funds tracked by Wall St. Rank hold MLYS as of Q4 2024.

  • PDT Partners reported no remaining Mineralys Therapeutics position as of Q4 2024 after selling out during the quarter.
  • PDT Partners sold 12,238 Mineralys Therapeutics shares in Q4 2024, an estimated $148K.
  • PDT Partners first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 3 quarters.
  • PDT Partners's Mineralys Therapeutics position peaked at $148K in Q3 2024.
  • 108 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2024.

Based on PDT Partners's 13F filing for Q4 2024, filed 14 Feb 2025.